Melanotan II vs Pramlintide
A detailed comparison to help you understand the differences and choose the right peptide for your research goals.
Melanotan II
Melanotan II is a synthetic peptide analog of α-MSH with broader receptor activity than Melanotan I. It produces tanning effects and has notable effects on sexual function and appetite suppression.
Full details →Pramlintide
Pramlintide (Symlin) is a synthetic analog of amylin, FDA-approved as an adjunct to insulin therapy in type 1 and type 2 diabetes. It helps control post-meal blood sugar spikes and promotes modest weight loss.
Full details →Side-by-Side Comparison
| Aspect | Melanotan II | Pramlintide |
|---|---|---|
| Dose Range | 250 mcg–1 mg | 15 mcg–120 mcg |
| Frequency | 1x daily | 3x daily |
| Cycle Length | 1–2 weeks | 12–52 weeks |
| Route | subcutaneous | subcutaneous |
| Mechanism | Non-selective melanocortin receptor agonist affecting MC1R (tanning), MC3R and MC4R (sexual function and appetite). This broader activity explains its multiple effects beyond tanning. | Mimics amylin's effects: slows gastric emptying, suppresses glucagon secretion after meals, and promotes satiety through central mechanisms. Complements insulin therapy. |
| Typical Dosage | Typical protocols: 0.25-0.5mg daily during loading phase for 1-2 weeks, then 0.5-1mg before UV exposure for maintenance. Start low to assess tolerance. | Type 1: Start 15mcg before meals, titrate to 30-60mcg. Type 2: Start 60mcg, may increase to 120mcg. Always with meal containing 30+ grams carbs or 250+ calories. |
| Administration | Subcutaneous injection. Usually combined with UV exposure for tanning effects. Nasal spray formulations exist but have lower bioavailability. | Subcutaneous injection immediately before major meals. Must reduce mealtime insulin by 50% when starting to prevent hypoglycemia. Never mix with insulin. |
| Side Effects | Nausea (common initially), facial flushing, spontaneous erections, increased libido, appetite suppression, and mole darkening. | Nausea (very common initially), headache, anorexia, vomiting, and abdominal pain. GI effects typically improve over time. |
| Best For |
What They Have in Common
Melanotan II, Pramlintide are both commonly used for:
Key Differences
Unique to Melanotan II:
Which Has Stronger Evidence?
- Fat Loss: Pramlintide has stronger research support.
| Goal | Melanotan II | Pramlintide |
|---|---|---|
| Fat Loss | low | medium |
Key Studies
Melanotan II
- Melanotan II nasal spray: a possible risk factor for oral mucosal malignant melanoma?
International journal of oral and maxillofacial surgery, 2025
- Melanotan II User Experience: A Qualitative Study of Online Discussion Forums.
Dermatology (Basel, Switzerland), 2021
- Melanotan II, a melanocortin agonist, partially rescues the impaired thermogenic capacity of pituitary adenylate cyclase-activating polypeptide deficient mice.
Experimental physiology, 2021
Pramlintide
- Chronic pramlintide decreases feeding via a reduction in meal size in male rats.
Peptides, 2024
- Pramlintide an Adjunct to Insulin Therapy: Challenges and Recent Progress in Delivery.
The Journal of pharmacology and experimental therapeutics, 2024
- Pramlintide for post-bariatric hypoglycaemia.
Diabetes, obesity & metabolism, 2022
Ready to Learn More?
Looking for trusted sources?